Literature DB >> 27899521

Venous Thrombotic Events After Liver Transplantation.

Annabel Blasi1, Virginia Hernandez2, Javier Fernandez3, Jordi Colmenero3, Joan Beltran1, Juan Carlos Garcia-Valdecasas4, Joan Carles Reverter5.   

Abstract

Thromboprophylaxis is not well defined after liver transplantation (LT). The aim of this study was to evaluate the incidence of splanchnic vein thrombosis (SVT) and nonsplanchnic vein thrombosis (NSVT) after LT. Liver transplantations performed between 2009 and 2013 in our institution were reviewed. Demographic, intraoperative, and postoperative data were recorded. Low-molecular-weight heparin was only administered postoperatively if intraoperative thrombectomy was performed or in patients preoperatively anticoagulated. Of a total of 328 patients, 72% were male with a median age of 56 years, score of model for end-stage liver disease 18 (11-23), and 88% had liver cirrhosis. The incidence of postoperative venous thrombotic events was 4.6%: 8 (2.4%) patients had SVT and 7 (2.1%) patients had NSVT. After logistic regression analysis, intraoperative thrombectomy and Child A classification emerged as risk factors for SVT (odds ratio [OR]: 77, 95% confidence interval [95% CI]: 14-421) and NSVT (OR: 20, 95% CI: 3-170), respectively. The incidence of SVT in patients who undergo intraoperative thrombectomy was 33%, whereas the incidence of NSVT in patients grouped as Child A was 7.5%. Our results suggest that thromboprophylaxis should be considered after LT in patients with cirrhosis grouped as Child A and in patients who undergo intraoperative thrombectomy.

Entities:  

Keywords:  deep venous thrombosis; thrombosis; thrombosis prophylaxis; venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27899521      PMCID: PMC6714689          DOI: 10.1177/1076029616680477

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  29 in total

1.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  An assessment of thromboelastometry to monitor blood coagulation and guide transfusion support in liver transplantation.

Authors:  Annabel Blasi; Joan Beltran; Arturo Pereira; Graciela Martinez-Palli; Abiguei Torrents; Jaume Balust; Elizabeth Zavala; Pilar Taura; Juan-Carlos Garcia-Valdecasas
Journal:  Transfusion       Date:  2012-02-05       Impact factor: 3.157

3.  Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.

Authors:  Lucio Amitrano; Maria Anna Guardascione; Antonella Menchise; Rossana Martino; Mariano Scaglione; Sabrina Giovine; Luigia Romano; Antonio Balzano
Journal:  J Clin Gastroenterol       Date:  2010-07       Impact factor: 3.062

4.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.

Authors:  Erica Villa; Calogero Cammà; Marco Marietta; Monica Luongo; Rosina Critelli; Stefano Colopi; Cristina Tata; Ramona Zecchini; Stefano Gitto; Salvatore Petta; Barbara Lei; Veronica Bernabucci; Ranka Vukotic; Nicola De Maria; Filippo Schepis; Aimilia Karampatou; Cristian Caporali; Luisa Simoni; Mariagrazia Del Buono; Beatrice Zambotto; Elena Turola; Giovanni Fornaciari; Susanna Schianchi; Anna Ferrari; Dominique Valla
Journal:  Gastroenterology       Date:  2012-07-20       Impact factor: 22.682

5.  Coagulation and fibrinolytic profiles and appropriate use of heparin after living-donor liver transplantation.

Authors:  Junichi Kaneko; Yasuhiko Sugawara; Sumihito Tamura; Junichi Togashi; Yuichi Matsui; Nobuhisa Akamatsu; Yoji Kishi; Masatoshi Makuuchi
Journal:  Clin Transplant       Date:  2005-12       Impact factor: 2.863

6.  Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism.

Authors:  Patrick G Northup; Matthew M McMahon; A Parker Ruhl; Scott E Altschuler; Agata Volk-Bednarz; Stephen H Caldwell; Carl L Berg
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

Review 7.  Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up.

Authors:  Francesca Romana Ponziani; Maria Assunta Zocco; Marco Senzolo; Maurizio Pompili; Antonio Gasbarrini; Alfonso Wolfango Avolio
Journal:  Transplant Rev (Orlando)       Date:  2014-01-27       Impact factor: 3.943

8.  Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients.

Authors:  John P Duffy; Johnny C Hong; Douglas G Farmer; Rafik M Ghobrial; Hasan Yersiz; Jonathan R Hiatt; Ronald W Busuttil
Journal:  J Am Coll Surg       Date:  2009-05       Impact factor: 6.113

9.  Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding.

Authors:  Nicolas M Intagliata; Zachary H Henry; Neeral Shah; Ton Lisman; Stephen H Caldwell; Patrick G Northup
Journal:  Liver Int       Date:  2013-06-12       Impact factor: 5.828

10.  Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation.

Authors:  Freeha Arshad; Jelle Adelmeijer; Hans Blokzijl; Aad van den Berg; Robert Porte; Ton Lisman
Journal:  F1000Res       Date:  2014-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.